Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ETNB - 89bio, Inc.

IEX Last Trade
7.97
0.080   1.004%

Share volume: 2,339
Last Updated: Thu 26 Dec 2024 04:30:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 4.47%

PREVIOUS CLOSE
CHG
CHG%
$7.89
0.08
1.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 25%
Dept financing 25%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-11.38%
3 Months
7.01%
6 Months
1.02%
1 Year
-27.16%
2 Year
-28.40%
Key data
Stock price
$7.97
P/E Ratio 
0.00
DAY RANGE
$7.66 - $7.90
EPS 
$0.00
52 WEEK RANGE
$7.27 - $16.63
52 WEEK CHANGE
-$28.53
MARKET CAP 
934.648 M
YIELD 
N/A
SHARES OUTSTANDING 
98.384 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
1.38
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,021,961
AVERAGE 30 VOLUME 
$1,253,848
Company detail
CEO: Rohan Palekar
Region: US
Website: 89bio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

89bio, Inc. focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21.

Recent news